Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the chronic sialorrhea market?

The market size for chronic sialorrhea has seen a robust expansion in the past few years. This market is projected to increase from $0.72 billion in 2024 to $0.76 billion in 2025, maintaining a compound annual growth rate (CAGR) of 6.5%. Factors contributing to the growth during the historic period include a rise in neurological disorders, a surge in population, heightened awareness and diagnoses, and growing demand for non-invasive treatments.

What will be the chronic sialorrhea market size in the future?

The market size of chronic sialorrhea is anticipated to experience robust growth in the upcoming years. The projections indicate an increase to $0.97 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.2%. Factors propelling growth in the predicted period include heightened awareness of treatment solutions, an escalated need for effective therapies, expanded healthcare spending, increased cases in children, and a surge in demand for oral gels and liquid. Noteworthy trends in the forecast period encompass remote patient monitoring via telemedicine, patient-focused care models, innovation in pharmacology, the incorporation of speech and occupational therapies, and the advent of long-lasting pharmaceuticals.

Get your chronic sialorrhea market report here!

https://www.thebusinessresearchcompany.com/report/chronic-sialorrhea-global-market-report

What main drivers are fueling expansion in the chronic sialorrhea market?

The rise in neurodegenerative disorders is anticipated to fuel the expansion of the chronic sialorrhea market in the future. Neurodegenerative disorders encompass a range of diseases marked by the gradual decay or death of nerve cells in the brain and spinal cord. The escalating number of these disorders can be attributed to genetic factors, family history, environmental influences, improved comprehension of disease processes, chronic health issues, and social and psychological factors. A usual complication of neurodegenerative disorders like Parkinson’s disease and ALS is chronic sialorrhea, leading to the need for specialized treatments to prevent aspiration, improve oral function, and enhance patient comfort. For instance, Parkinson’s UK reported in September 2023 that around 153,000 individuals in the UK are currently diagnosed with Parkinson’s. With the graying populace, this figure is expected to spike by 20% to an estimated 172,000 by 2030. Thus, the escalating incidence of neurodegenerative disorders will spur the chronic sialorrhea market’s growth.

What key areas define the segmentation of the global chronic sialorrhea market?

The chronic sialorrhea market covered in this report is segmented –

1) By Treatment Type: Pharmacological Treatments, Botulinum Toxin Injections, Surgical Interventions, Medical Devices And Assistive Therapies

2) By Route Of Administration: Oral Medications, Injectable Treatments, Topical Applications

3) By Patient Population: Pediatric Patients, Adult Patients

4) By End-User: Hospitals And Specialty Clinics, Rehabilitation Centers, Homecare Settings

Subsegments:

1) By Pharmacological Treatments: Anticholinergic Medications, Antidepressants, Alpha-adrenergic Agonists, Salivary Gland Modulators

2) By Botulinum Toxin Injections: Botulinum Toxin Type A (Botox), Botulinum Toxin Type B (Myobloc), Localized Salivary Gland Injections

3) By Surgical Interventions: Sialendoscopy, Salivary Gland Duct Dilation or Stenting, Parotid Duct Surgery, Submandibular Gland Removal (Sialadenectomy)

4) By Medical Devices And Assistive Therapies: Oral Dryness Devices, Salivary Stimulation Devices, Lip and Mouth Exercises, Artificial Salivary Glands

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21149&type=smp

Who are the dominant players expanding their reach in the chronic sialorrhea market?

Major companies operating in the chronic sialorrhea market are Pfizer Inc., Eisai Co. Ltd., Ipsen Pharmaceuticals Inc., Aurobindo Pharma Limited, Shionogi Inc., Supernus Pharmaceuticals Inc., Granules India Limited, Hugel Inc., Medy-Tox Inc., Gufic Biosciences Limited, US WorldMeds LLC, Proveca Limited, Neos Therapeutics Inc., Merz Therapeutics GmbH, Taj Pharma India Limited, Meitheal Pharmaceuticals, Clini Experts Services Private Limited, NeuroHealing Pharmaceuticals Inc., ExCEEd Orphan Pharmaceuticals AG, Solstice Neurosciences Inc.

What key trends are currently impacting the chronic sialorrhea market’s development?

Leading businesses in the chronic sialorrhoea market are prioritizing the creation of novel treatment methods, such as oral remedies, as they offer an easier mode of administration for patients, non-invasive management for chronic sialorrhoea in youngsters and boast increased safety and efficacy with fewer side effects. Oral solutions refer to liquefied medications designed for oral administration, usually containing an active ingredient dissolved in a solvent for easy consumption. An example is the 2023 launch in France of Sialanar (glycopyrronium bromide), an innovative product from UK-based Proveca Pharma Ltd., meant for treating intense chronic sialorrhoea in children having neurological disorders. This unique liquid product is formulated for straightforward administration and precise dosage, thus extremely suitable for paediatric patients who find it challenging to take solid drugs. It holds a proven safety and efficacy record, assists in enhancing life quality by lessening extreme salivation, a frequent issue in neurodevelopmental disorders such as cerebral palsy.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21149

Which regions are emerging as leaders in the chronic sialorrhea market?

North America was the largest region in the chronic sialorrhea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic sialorrhea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Bladder Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2025

https://thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: